RenovoRx, Inc.
NASDAQ:RNXTBiotechnology
-$0.01 today
- Market cap
- $54.04M
- Beta
- 0.99
- P/E (TTM)
- -3.4
- EPS (TTM)
- -$0.32
Volume 0.84M
Average 0.29M
RNXT Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
RenovoRx, Inc.NASDAQ: RNXT
Total Assets · Q1 FY2026 · quarter ended Mar 2026
Total assets falls 12.8% from a year ago
Total assets stood at $13.96M at the end of Q1 FY2026, down 12.8% from a year earlier and up 72.5% from the prior quarter. Over 3 fiscal years it compounded at +3.7% a year.
Context
- Total assets increased in 1 of the last 3 fiscal years.
What to watch
Whether total assets keeps falling in the next quarterly balance sheet after a -12.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
USD · from the balance sheet
- Latest · FY2025
- 8.1M USD
- Year-over-year change
- -0.3%
- 4-year CAGR
- -16.0%
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.1M | -0.3% |
| FY2024 | 2024-12-31 | 8.12M | +453.8% |
| FY2023 | 2023-12-31 | 1.47M | -79.8% |
| FY2022 | 2022-12-31 | 7.27M | -55.4% |
| FY2021 | 2021-12-31 | 16.29M | — |
Total Assets vs competitors
How RNXT compares with its peers on the latest reported figures
- RNXT's Mar 2026 total assets of $13.96M is the 5th highest of the 6 companies compared; the peer median is $19.16M.
- Its year-over-year change of -12.8% is the 3rd highest of 6, against a peer median of -19.1%.
- Over three fiscal years its annual growth of +3.7% compares with a peer median of -6.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
| Dec 2025 | $107.33M | -19.1% | -35.6% | |
| Mar 2026 | $35.32M | +197.7% | -6.9% | |
| Mar 2026 | $19.16M | +13.7% | -4.9% | |
| Mar 2026 | $16.24M | -39.2% | -16.4% | |
| Mar 2026 | $13.96M | -12.8% | +3.7% | |
| Mar 2026 | $7.22M | -65.8% | +472.4% | |
| Peer median (excluding RNXT) | $19.16M | -19.1% | -6.9% | |
Competitors are the stored peer set for RNXT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
RenovoRx, Inc.
NASDAQ:RNXT
Intrinsic Alpha fair value
Locked
Current Price
$1.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.